Establishing an immunocompromised porcine model of human cancer for novel therapy development with pancreatic adenocarcinoma and irreversible electroporation.

MLA

Hendricks-Wenger, Alissa, et al. “Establishing an Immunocompromised Porcine Model of Human Cancer for Novel Therapy Development with Pancreatic Adenocarcinoma and Irreversible Electroporation.” Scientific Reports, vol. 11, no. 1, Apr. 2021, pp. 1–14. EBSCOhost, https://doi.org/10.1038/s41598-021-87228-5.

APA

Hendricks-Wenger, A., Aycock, K. N., Nagai-Singer, M. A., Coutermarsh-Ott, S., Lorenzo, M. F., Gannon, J., Uh, K., Farrell, K., Beitel-White, N., Brock, R. M., Simon, A., Morrison, H. A., Tuohy, J., Clark-Deener, S., Vlaisavljevich, E., Davalos, R. V., Lee, K., & Allen, I. C. (2021). Establishing an immunocompromised porcine model of human cancer for novel therapy development with pancreatic adenocarcinoma and irreversible electroporation. Scientific Reports, 11(1), 1–14. https://doi.org/10.1038/s41598-021-87228-5

Chicago

Hendricks-Wenger, Alissa, Kenneth N. Aycock, Margaret A. Nagai-Singer, Sheryl Coutermarsh-Ott, Melvin F. Lorenzo, Jessica Gannon, Kyungjun Uh, et al. 2021. “Establishing an Immunocompromised Porcine Model of Human Cancer for Novel Therapy Development with Pancreatic Adenocarcinoma and Irreversible Electroporation.” Scientific Reports 11 (1): 1–14. doi:10.1038/s41598-021-87228-5.